Latest News and Press Releases
Want to stay updated on the latest news?
Search Results
Everything
Search Filters
-
TransCode Therapeutics Announces Effective Date for 1-for-33 Reverse Stock Split
-
TransCode Therapeutics, Inc. Announces $8 Million Private Placement
-
TransCode Therapeutics Announces 1-for-33 Reverse Stock Split
-
Open Letter to Shareholders
-
TransCode Therapeutics Announces Nasdaq Extension to Re-gain Compliance
-
TransCode Therapeutics Announces Safety Review Committee Approval of Second Cohort Opening in Phase 1 TTX-MC138 Clinical Trial Following Favorable Review o
-
TransCode Therapeutics Completes Initial Dosing of First Co-hort in Phase 1 Clinical Trial with TTX-MC138, a microRNA-Targeted Technology
-
TransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with First-in-Class Lead Therapeutic Candidate
-
TransCode Therapeutics Announces Publication of Study with Lead Therapeutic Candi-date Revealing Mechanisms Behind Candidate’s Preclinical Efficacy Against
-
TransCode Therapeutics Awarded $2 Million NIH Grant to Support Clinical Evaluation of Lead Candidate
TransCode Therapeutics Awarded $2 Million NIH Grant to Support Clinical Evaluation of Lead Candidate